Volv Global continues to shape the future of AI in healthcare. This November, at Frontiers Health 2025 in Berlin, CEO…
Léon van Wouwe, Clinical Innovation Director, Volv Global Since Volv Global first started attending the World Orphan Drug Congress, we…
How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency…
Volv Global at WODC Europe 2025 - Where Technology Meets Human Volv Global sits at the crucial intersection between technology…
Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at…
Volv Global presented two posters at ATS 2025, in collaboration with Takeda The posters were the result of work to…
Volv Global is pleased to attend Swiss Biotech Day 2025! Meet us at Messe Basel, 5th-6th May, to find out…
On the occasion of international Rare Disease Day 2025, we are beyond thrilled to host the voice of patient advocate…
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…